Vendor comparison · 2026
TB-500 vendors: 29 compared on COAs and price
Tissue & recoveryAlso known as Thymosin Beta-4 fragment
Evidence tier
Multiple human trials
4 human trials · 1 observational · 1 preclinical
- Vendors carrying it
- 29
- 27 with a listed price
- Vendors with checkable COAs
- 12
- 13 publish any certificate
- Lots tested
- 25
- 24 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 18 Sept 2026
- oldest 4 Feb 2026
- Laboratories named
- 9
- most often Freedom Diagnostics Testing
- Median label gap
- 5.0%
- 52% of lots within 5% of label
- Median purity
- 99.69%
- 24 of 25 lots at 99% or above
- Lowest price per mg
- $1.18
- peer median $6.00
- Publications located
- 1.1k
- researched since 1979
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable TB-500 testing in this index: 6 lots assayed by ILS Laboratories, the newest on 3 Sept 2026. The lowest listed price is $1.18 per mg at Hydro Research Peptides, against a peer median of $6.00. 29 vendors carrying TB-500 are compared below. 12 publish at least one certificate naming a checkable laboratory, 25 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying TB-500
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | $3.00 (50%) | 0 | — | — | — | — | |
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $3.50 (58%) | 6 / 6 | ILS Laboratories | 99.8% | 4.6% | ||
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 92.298% | $4.00 (67%) | 1 / 1 | Freedom Diagnostics Testing | 99.3% | 8.8% | ||
| 4 | Ascend ScienceISO/IEC 17025 | 90.194% | $4.90 (82%) | 0 | — | — | — | — | |
| 5 | One Aminos | 88.589% | $4.00 (67%) | 1 / 1 | United Laboratories | 99.7% | 25.7% | ||
| 6 | PeptidePlugs | 87.694% | $5.00 (83%) | 3 / 3 | Freedom Diagnostics Testing | 99.5% | 24.8% | ||
| 7 | Bench Grade Peptides | 8789% | $4.10 (68%) | 4 / 4 | AV Analytics, Freedom Diagnostics Testing | 99.5% | 15.2% | ||
| 8 | Hydro Research PeptidesISO/IEC 17025 | 85.689% | $1.18 (30%) | 0 | — | — | — | — | no reportVisit site |
| 9 | NeuroLabs Research | 84.891% | $4.79 (80%) | 0 | — | — | — | — | no reportVisit site |
| 10 | Modern AminosISO/IEC 17025COAs need an account | 81.297% | $5.90 (98%) | 0 | — | — | — | — | no reportVisit site |
| 11 | Simple Peptide | 77.492% | $6.50 (108%) | 1 / 1 | Freedom Diagnostics Testing | 99.5% | 1.0% | ||
| 12 | Transition Biotech | 7791% | $5.50 (92%) | 1 / 1 | Kovera Labs | 99.6% | 14.2% | ||
| 13 | Koi PeptidesAge-gated COAs | 76.492% | $6.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Good Science Bio | 74.271% | $4.00 (67%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Prime PeptidesISO/IEC 17025 | 7496% | $6.50 (108%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Northline LabsISO/IEC 17025 | 7195% | — | 1 / 1 | ILS Laboratories | 99.5% | 1.5% | ||
| 17 | CuroISO/IEC 17025 | 70.997% | $10.80 (180%) | 1 / 1 | BTLabs | 99.6% | 20.0% | ||
| 18 | Protide HealthAge-gated COAs | 69.892% | $8.50 (142%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Ascension Peptides | 68.489% | $10.80 (180%) | 1 / 1 | MZ Biolabs | 100.0% | 2.2% | ||
| 20 | True Research Labs | 6168% | $6.90 (115%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Licensed Peptides | 60.687% | $10.00 (167%) | 1 / 1 | Vanguard Laboratory | 99.8% | 0.5% | ||
| 22 | Mile High Compounds | 60.591% | $6.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Vial Drop Labs | 59.474% | — | 3 / 3 | KMD Analytical (KMD Group LLC) | 99.3% | 1.1% | ||
| 24 | Improved Peptides | 58.887% | $8.50 (142%) | 0 / 1 | Not named | 99.1% | 17.6% | ||
| 25 | Vertex Labs | 56.172% | $9.33 (156%) | 0 | — | — | — | — | no reportVisit site |
| 26 | Evolve Peptides | 55.468% | $9.00 (150%) | 0 | — | — | — | — | no reportVisit site |
| 27 | BioLongevity Labs | 54.572% | $16.50 (250%) | 0 | — | — | — | — | no reportVisit site |
| 28 | GenX Peptides | 52.869% | $16.50 (250%) | 0 | — | — | — | — | no reportVisit site |
| 29 | Biotech Peptides | 49.160% | $12.40 (207%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of TB-500 is on file. All 25 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
24 of 25 lots at 99% or above; median 99.69%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 1 |
| 98–99% | 0 |
| 99–99.5% | 6 |
| ≥99.5% | 18 |
52% of lots within 5% of the labelled mass; median gap 5.0%.
| Range | lots |
|---|---|
| ≤2% | 7 |
| 2–5% | 5 |
| 5–10% | 5 |
| 10–20% | 2 |
| >20% | 6 |
27 vendors, $1.18 to $16.50; median $6.00.
| Range | vendors |
|---|---|
| $0–$5.00 | 9 |
| $5.00–$10.00 | 12 |
| $10.00–$15.00 | 4 |
| $15.00–$20.00 | 2 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 7 | 4 | 28% | Public lookup |
| ILS LaboratoriesUS | 7 | 2 | 28% | Public lookup |
| KMD Analytical (KMD Group LLC)US | 3 | 1 | 12% | Public lookup |
| AV Analytics | 2 | 1 | 8% | No public lookup found |
| BTLabs | 1 | 1 | 4% | No public lookup found |
| Kovera Labs | 1 | 1 | 4% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 4% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 4% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 4% | No public lookup found |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1979 — 47 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
1,063 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 25 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.41 pts purity across lots, mean label deviation 10.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
29 of 29 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
24 of 25 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is TB-500?
A synthetic peptide fragment related to the naturally occurring protein thymosin beta-4. Supplied as a lyophilised powder.
Studied in published research for tissue repair, recovery and flexibility.
Regulatory status
Labeled by vendors for laboratory research use only. Not an approved medicine in any major jurisdiction.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
The published literature is largely preclinical and concerns the parent protein rather than the fragment sold under this name. Vendors frequently cite thymosin beta-4 research when listing TB-500; the two are not identical, and this index records that distinction where a vendor makes the substitution.
- Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids — Stem cell reports (2025)
Peer-reviewed article indexed in PubMed, published in Stem cell reports (2025).
- beta-Thymosins — Annals of the New York Academy of Sciences (2007)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (2007).
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications — Expert opinion on biological therapy (2012)
Peer-reviewed article indexed in PubMed, published in Expert opinion on biological therapy (2012).
- Identification of glutamine as a potential therapeutic target in dry eye disease — Signal transduction and targeted therapy (2025)
Peer-reviewed article indexed in PubMed, published in Signal transduction and targeted therapy (2025).
- Cardioprotection by Thymosin Beta 4 — Vitamins and hormones (2016)
Peer-reviewed article indexed in PubMed, published in Vitamins and hormones (2016).
- The beta-thymosin enigma — Annals of the New York Academy of Sciences (2007)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (2007).
- Thymosin beta 4 interactions — Vitamins and hormones (2003)
Peer-reviewed article indexed in PubMed, published in Vitamins and hormones (2003).
- Thymosin beta 4 — Methods in enzymology (1985)
Peer-reviewed article indexed in PubMed, published in Methods in enzymology (1985).
Indexed studies5 human-evidence of 6
- Published work on thymosin beta-4, the parent protein of TB-500 — Animal
This literature concerns thymosin beta-4, the full parent protein — not the fragment sold as TB-500. Vendors frequently cite this body of work when listing TB-500; the two are not the same molecule, and evidence about one is not evidence about the other.
- Early-phase human work on thymosin beta-4 — Human — controlled trial
A small number of early-phase human studies of the parent protein exist in the listed literature. None were carried through to marketing approval in any jurisdiction, and none concern the TB-500 fragment as sold.
- Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis — Case report, 1993
Patients with malignant thymoma rarely may also have a peripheral T-cell lymphocytosis. "Lymphocyte spillover" from the thymus into the peripheral blood as well as a second, associated neoplasm (ie, T-cell chronic lymphocytic leukemia) are two hypotheses that have been proposed to explain this clinical phenomenon. We describe another patient with a lymphocyte-rich malignant thymoma associated with peripheral T-cell lymphocytosis. At the time of initial diagnosis, the patient'…
- Thymosins: structure, function and therapeutic applications — Human — controlled trial, 1984
Using a partially purified preparation, thymosin fraction 5, we have documented that thymosin can correct many of the immunological deficiencies resulting from the lack of thymosin function in animal models and in humans. Ongoing studies indicate that there is a family of biologically active peptides within fraction 5 that act on T-cell subpopulations to maintain normal immunological reactivity. Several of these peptides have been purified to homogeneity. Two peptides, thymos…
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers — Human — controlled trial, 2010
Synthetic thymosin beta 4 (Tbeta4) may have a potential use in promoting myocardial cell survival during acute myocardial infarction. Four cohorts, with 10 healthy subjects each, were given a single intravenous dose of placebo or synthetic Tbeta4. Cohorts received ascending doses of either 42, 140, 420, or 1260 mg. Following safety review, subjects were given the same dose regimen daily for 14 days. Safety evaluations, incidence of Treatment-Emergent Adverse Events, and pharm…
- The effect of thymosin treatment of venous ulcers — Human — controlled trial, 2010
Venous ulcers are responsible for about 70% of the chronic ulcers of the lower limbs. Standard of care includes compression, dressings, debridement of devitalized tissue, and infection control. Thymosin beta 4 (Tbeta4), a synthetic copy of the naturally occurring 43 amino-acid peptide, has been found to have wound healing and anti-inflammatory properties, and is thought to exert its therapeutic effect through promotion of keratinocyte and endothelial cell migration, increased…
Evidence digest
What the research on TB-500 actually shows
Almost all literature cited for TB-500 concerns thymosin beta-4, the full parent protein — not the fragment sold under the TB-500 name. This distinction is the whole story for this compound. A vendor citing thymosin beta-4 research on a TB-500 product page is citing work about a different molecule, and the indexed literature contains no controlled human trial of the fragment as sold.
4 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.